|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.72 USD | +2.14% |
|
+8.09% | +8.51% |
| 05-06 | Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating | MT |
| 05-02 | UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating | MT |
Bio-Techne Corporation reported earnings results for the first quarter ended September 30, 2023. For the first quarter, the company reported sales was USD 276.94 million compared to USD 269.66 million a year ago. Net income was USD 50.99 million compared to USD 89.56 million a year ago.
Basic earnings per share from continuing operations was USD 0.32 compared to USD 0.57 a year ago. Diluted earnings per share from continuing operations was USD 0.31 compared to USD 0.55 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.51% | 12.92B | |
| +29.77% | 48.16B | |
| -1.02% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +10.16% | 25.59B | |
| -23.07% | 18.96B | |
| +28.77% | 12.03B | |
| -1.92% | 11.77B | |
| +20.94% | 11.73B |
BIO-TECHNE CORPORATION 